Table 3.
Summary of adverse events
| Outcome | Number of studies | Total number of patients included
|
RR (95% CrI) | Posterior probability | SD | |
|---|---|---|---|---|---|---|
| Triple therapy | TIO monotherapy | |||||
| Total adverse events | 5 | 800 | 813 | 1.12 (0.87–1.40) | P (RR >1) =0.84 | 0.14 |
| Severe adverse events | 6 | 1,031 | 1,051 | 0.62 (0.17–1.25) | P (RR <1) =0.93 | 0.29 |
| Pneumonia | 4 | 829 | 856 | 1.07 (0.05–4.28) | P (RR >1) =0.27 | 3.63 |
| Oral candidiasis | 3 | 647 | 656 | 3.63 (0.46–12.82) | P (RR >1) =0.88 | 4.53 |
Abbreviations: TIO, tiotropium; RR, relative risk; CrI, credible interval; SD, standard deviation (between studies).